Company Overview and News

 
Concur baut Geschäft in China aus

2016-12-01 prnewswire
Mit China DataCom Corporation unterstützt Concur Unternehmen in China bei lokaler Anpassung, Globalisierung und der digitalen Transformation von T&E-Prozessen

 
Concur ampliará sus negocios en China

2016-12-01 prnewswire
Junto con China DataCom Corporation, la expansión de Concur en China ayudará a las empresas en la localización, globalización y transformación digital de los procesos de gestión de viajes y gastos

 
Concur breidt zakelijke activiteiten in China uit

2016-12-01 prnewswire
In samenwerking met China DataCom Corporation zorgt de uitbreiding van Concur in China voor de ondersteuning van bedrijven bij lokalisatie, globalisering en digitale transformatie van reis- en onkostenbeheer

 
Concur skal utvide sin virksomhet i Kina

2016-12-01 prnewswire
Sammen med China DataCom Corporation vil Concurs expansjon i Kina bistå selskaper med  lokalisering, globalisering og digital transformasjon av T&E-prosesser, ('Travel & Expense' eller Reise- og reiseutgifter)

 
Concur étend son activité sur le marché chinois

2016-12-01 prnewswire
Mené de concert avec China DataCom Corporation, le développement de Concur en Chine permet aux entreprises d'assurer localement comme à l'international la transformation digitale de leur gestion des frais et déplacements professionnels.

 
Concur to Expand Business in China

2016-12-01 prnewswire
Together with China DataCom Corporation, Concur's expansion in China will help companies with localization, globalization and digital transformation of T&E processes 

 
Asian Tech Stock Weekly Review (August 31 - September 6, 2009)

2016-11-03 seekingalpha
• NEC Corp. (OTC:NELTY), Hitachi Ltd. (HIT) and Casio Computer Co. (OTCPK:CSIOY) plan to merge their mobile handset operations. This will create the country's second-largest cellphone maker by shipments after Sharp Corp. (OTCPK:SHCAY). The Japanese cellphone makers aim to boost profitability by consolidating operations to save money in a domestic market nearing saturation. A consolidation of the three players would help lessen their spending on development costs and ride out the tough local market.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...